New Treatment Approach in Indian Visceral Leishmaniasis: Single-Dose Liposomal Amphotericin B Followed by Short-Course Oral Miltefosine
Background. In Bihar, India, home to nearly one-half of the world's burden of visceral leishmaniasis, drug resistance has ended the usefulness of pentavalent antimony, which is the traditional first-line treatment. Although monotherapy with other agents is available, the use of 2 drugs with dif...
Saved in:
| Published in | Clinical infectious diseases Vol. 47; no. 8; pp. 1000 - 1006 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Chicago, IL
The University of Chicago Press
15.10.2008
University of Chicago Press Oxford University Press |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1058-4838 1537-6591 1537-6591 |
| DOI | 10.1086/591972 |
Cover
| Abstract | Background. In Bihar, India, home to nearly one-half of the world's burden of visceral leishmaniasis, drug resistance has ended the usefulness of pentavalent antimony, which is the traditional first-line treatment. Although monotherapy with other agents is available, the use of 2 drugs with different modes of action might increase efficacy, shorten treatment duration, enhance compliance, and/or reduce the risk of parasite resistance. To test the feasibility of a new approach to combination therapy in visceral leishmaniasis (also known a kala-azar), we treated Indian patients with a single infusion of liposomal amphotericin B (L-AmB), followed 1 day later by short-course oral miltefosine. Methods. We used a randomized, noncomparative, group-sequential, triangular design and assigned 181 subjects to treatment with 5 mg/kg of L-AmB alone (group A; 45 subjects), 5 mg/kg of L-AmB followed by miltefosine for 10 days (group B; 46 subjects) or 14 days (group C; 45 subjects), or 3.75 mg/kg of L-AmB followed by miltefosine for 14 days (group D; 45 subjects). When it became apparent that all regimens were effective, 45 additional, nonrandomized patients were assigned to receive 5 mg/kg of L-AmB followed by miltefosine for 7 days (group E). Results. Each regimen was satisfactorily tolerated, and all 226 subjects showed initial apparent cure responses. Nine months after treatment, final cure rates were similar: group A, 91% (95% confidence interval [CI], 78%–97%]; group B, 98% (95% CI, 87%–100%); group C, 96% (95% CI, 84%–99%]; group D, 96% (95% CI, 84%–99%); and group E, 98% (95% CI, 87%–100%). Conclusions. These results suggest that treatment with single-dose L-AmB followed by 7–14 days of miltefosine is active against Indian kala-azar. This short-course, sequential regimen warrants additional testing in India and in those regions of endemicity where visceral leishmaniasis may be more difficult to treat. Trial registration. ClinicalTrials.gov identifier: NCT00370825. |
|---|---|
| AbstractList | In Bihar, India, home to nearly one-half of the world's burden of visceral leishmaniasis, drug resistance has ended the usefulness of pentavalent antimony, which is the traditional first-line treatment. Although monotherapy with other agents is available, the use of 2 drugs with different modes of action might increase efficacy, shorten treatment duration, enhance compliance, and/or reduce the risk of parasite resistance. To test the feasibility of a new approach to combination therapy in visceral leishmaniasis (also known a kala-azar), we treated Indian patients with a single infusion of liposomal amphotericin B (L-AmB), followed 1 day later by short-course oral miltefosine. We used a randomized, noncomparative, group-sequential, triangular design and assigned 181 subjects to treatment with 5 mg/kg of L-AmB alone (group A; 45 subjects), 5 mg/kg of L-AmB followed by miltefosine for 10 days (group B; 46 subjects) or 14 days (group C; 45 subjects), or 3.75 mg/kg of L-AmB followed by miltefosine for 14 days (group D; 45 subjects). When it became apparent that all regimens were effective, 45 additional, nonrandomized patients were assigned to receive 5 mg/kg of L-AmB followed by miltefosine for 7 days (group E). Each regimen was satisfactorily tolerated, and all 226 subjects showed initial apparent cure responses. Nine months after treatment, final cure rates were similar: group A, 91% (95% confidence interval [CI], 78%-97%]; group B, 98% (95% CI, 87%-100%); group C, 96% (95% CI, 84%-99%]; group D, 96% (95% CI, 84%-99%); and group E, 98% (95% CI, 87%-100%). These results suggest that treatment with single-dose L-AmB followed by 7-14 days of miltefosine is active against Indian kala-azar. This short-course, sequential regimen warrants additional testing in India and in those regions of endemicity where visceral leishmaniasis may be more difficult to treat. Background. In Bihar, India, home to nearly one-half of the world's burden of visceral leishmaniasis, drug resistance has ended the usefulness of pentavalent antimony, which is the traditional first-line treatment. Although monotherapy with other agents is available, the use of 2 drugs with different modes of action might increase efficacy, shorten treatment duration, enhance compliance, and/or reduce the risk of parasite resistance. To test the feasibility of a new approach to combination therapy in visceral leishmaniasis (also known a kala-azar), we treated Indian patients with a single infusion of liposomal amphotericin B (L-AmB), followed 1 day later by short-course oral miltefosine. Methods. We used a randomized, noncomparative, group-sequential, triangular design and assigned 181 subjects to treatment with 5 mg/kg of L-AmB alone (group A; 45 subjects), 5 mg/kg of L-AmB followed by miltefosine for 10 days (group B; 46 subjects) or 14 days (group C; 45 subjects), or 3.75 mg/kg of L-AmB followed by miltefosine for 14 days (group D; 45 subjects). When It became apparent that all regimens were effective, 45 additional, nonrandomized patients were assigned to receive 5 mg/kg of L-AmB followed by miltefosine for 7 days (group E). Results. Each regimen was satisfactorily tolerated, and all 226 subjects showed initial apparent cure responses. Nine months after treatment, final cure rates were similar: group A, 91% (95% confidence interval [CI], 78%-97%]; group B, 98% (95% CI, 87%-100%); group C, 96% (95% CI, 84%-99%]; group D, 96% (95% CI, 84%-99%); and group E, 98% (95% CI, 87%-100%). Conclusions. These results suggest that treatment with single-dose L-AmB followed by 7-14 days of miltefosine is active against Indian kala-azar. This short-course, sequential regimen warrants additional testing in India and in those regions of endemicity where visceral leishmaniasis may be more difficult to treat. In Bihar, India, home to nearly one-half of the world's burden of visceral leishmaniasis, drug resistance has ended the usefulness of pentavalent antimony, which is the traditional first-line treatment. Although monotherapy with other agents is available, the use of 2 drugs with different modes of action might increase efficacy, shorten treatment duration, enhance compliance, and/or reduce the risk of parasite resistance. To test the feasibility of a new approach to combination therapy in visceral leishmaniasis (also known a kala-azar), we treated Indian patients with a single infusion of liposomal amphotericin B (L-AmB), followed 1 day later by short-course oral miltefosine.BACKGROUNDIn Bihar, India, home to nearly one-half of the world's burden of visceral leishmaniasis, drug resistance has ended the usefulness of pentavalent antimony, which is the traditional first-line treatment. Although monotherapy with other agents is available, the use of 2 drugs with different modes of action might increase efficacy, shorten treatment duration, enhance compliance, and/or reduce the risk of parasite resistance. To test the feasibility of a new approach to combination therapy in visceral leishmaniasis (also known a kala-azar), we treated Indian patients with a single infusion of liposomal amphotericin B (L-AmB), followed 1 day later by short-course oral miltefosine.We used a randomized, noncomparative, group-sequential, triangular design and assigned 181 subjects to treatment with 5 mg/kg of L-AmB alone (group A; 45 subjects), 5 mg/kg of L-AmB followed by miltefosine for 10 days (group B; 46 subjects) or 14 days (group C; 45 subjects), or 3.75 mg/kg of L-AmB followed by miltefosine for 14 days (group D; 45 subjects). When it became apparent that all regimens were effective, 45 additional, nonrandomized patients were assigned to receive 5 mg/kg of L-AmB followed by miltefosine for 7 days (group E).METHODSWe used a randomized, noncomparative, group-sequential, triangular design and assigned 181 subjects to treatment with 5 mg/kg of L-AmB alone (group A; 45 subjects), 5 mg/kg of L-AmB followed by miltefosine for 10 days (group B; 46 subjects) or 14 days (group C; 45 subjects), or 3.75 mg/kg of L-AmB followed by miltefosine for 14 days (group D; 45 subjects). When it became apparent that all regimens were effective, 45 additional, nonrandomized patients were assigned to receive 5 mg/kg of L-AmB followed by miltefosine for 7 days (group E).Each regimen was satisfactorily tolerated, and all 226 subjects showed initial apparent cure responses. Nine months after treatment, final cure rates were similar: group A, 91% (95% confidence interval [CI], 78%-97%]; group B, 98% (95% CI, 87%-100%); group C, 96% (95% CI, 84%-99%]; group D, 96% (95% CI, 84%-99%); and group E, 98% (95% CI, 87%-100%).RESULTSEach regimen was satisfactorily tolerated, and all 226 subjects showed initial apparent cure responses. Nine months after treatment, final cure rates were similar: group A, 91% (95% confidence interval [CI], 78%-97%]; group B, 98% (95% CI, 87%-100%); group C, 96% (95% CI, 84%-99%]; group D, 96% (95% CI, 84%-99%); and group E, 98% (95% CI, 87%-100%).These results suggest that treatment with single-dose L-AmB followed by 7-14 days of miltefosine is active against Indian kala-azar. This short-course, sequential regimen warrants additional testing in India and in those regions of endemicity where visceral leishmaniasis may be more difficult to treat.CONCLUSIONSThese results suggest that treatment with single-dose L-AmB followed by 7-14 days of miltefosine is active against Indian kala-azar. This short-course, sequential regimen warrants additional testing in India and in those regions of endemicity where visceral leishmaniasis may be more difficult to treat.ClinicalTrials.gov identifier: NCT00370825 .TRIAL REGISTRATIONClinicalTrials.gov identifier: NCT00370825 . Background . In Bihar, India, home to nearly one-half of the world's burden of visceral leishmaniasis, drug resistance has ended the usefulness of pentavalent antimony, which is the traditional first-line treatment. Although monotherapy with other agents is available, the use of 2 drugs with different modes of action might increase efficacy, shorten treatment duration, enhance compliance, and/or reduce the risk of parasite resistance. To test the feasibility of a new approach to combination therapy in visceral leishmaniasis (also known a kala-azar), we treated Indian patients with a single infusion of liposomal amphotericin B (L-AmB), followed 1 day later by short-course oral miltefosine. Methods . We used a randomized, noncomparative, group-sequential, triangular design and assigned 181 subjects to treatment with 5 mg/kg of L-AmB alone (group A; 45 subjects), 5 mg/kg of L-AmB followed by miltefosine for 10 days (group B; 46 subjects) or 14 days (group C; 45 subjects), or 3.75 mg/kg of L-AmB followed by miltefosine for 14 days (group D; 45 subjects). When it became apparent that all regimens were effective, 45 additional, nonrandomized patients were assigned to receive 5 mg/kg of L-AmB followed by miltefosine for 7 days (group E). Results . Each regimen was satisfactorily tolerated, and all 226 subjects showed initial apparent cure responses. Nine months after treatment, final cure rates were similar: group A, 91% (95% confidence interval [CI], 78%-97%]; group B, 98% (95% CI, 87%-100%); group C, 96% (95% CI, 84%-99%]; group D, 96% (95% CI, 84%-99%); and group E, 98% (95% CI, 87%-100%). Conclusions . These results suggest that treatment with single-dose L-AmB followed by 7-14 days of miltefosine is active against Indian kala-azar. This short-course, sequential regimen warrants additional testing in India and in those regions of endemicity where visceral leishmaniasis may be more difficult to treat. Trial registration . ClinicalTrials.gov identifier: NCT00370825. Background. In Bihar, India, home to nearly one-half of the world's burden of visceral leishmaniasis, drug resistance has ended the usefulness of pentavalent antimony, which is the traditional first-line treatment. Although monotherapy with other agents is available, the use of 2 drugs with different modes of action might increase efficacy, shorten treatment duration, enhance compliance, and/or reduce the risk of parasite resistance. To test the feasibility of a new approach to combination therapy in visceral leishmaniasis (also known a kala-azar), we treated Indian patients with a single infusion of liposomal amphotericin B (L-AmB), followed 1 day later by short-course oral miltefosine. Methods. We used a randomized, noncomparative, group-sequential, triangular design and assigned 181 subjects to treatment with 5 mg/kg of L-AmB alone (group A; 45 subjects), 5 mg/kg of L-AmB followed by miltefosine for 10 days (group B; 46 subjects) or 14 days (group C; 45 subjects), or 3.75 mg/kg of L-AmB followed by miltefosine for 14 days (group D; 45 subjects). When it became apparent that all regimens were effective, 45 additional, nonrandomized patients were assigned to receive 5 mg/kg of L-AmB followed by miltefosine for 7 days (group E). Results. Each regimen was satisfactorily tolerated, and all 226 subjects showed initial apparent cure responses. Nine months after treatment, final cure rates were similar: group A, 91% (95% confidence interval [CI], 78%–97%]; group B, 98% (95% CI, 87%–100%); group C, 96% (95% CI, 84%–99%]; group D, 96% (95% CI, 84%–99%); and group E, 98% (95% CI, 87%–100%). Conclusions. These results suggest that treatment with single-dose L-AmB followed by 7–14 days of miltefosine is active against Indian kala-azar. This short-course, sequential regimen warrants additional testing in India and in those regions of endemicity where visceral leishmaniasis may be more difficult to treat. Trial registration. ClinicalTrials.gov identifier: NCT00370825. In Bihar, India, home to nearly one-half of the world's burden of visceral leishmaniasis, drug resistance has ended the usefulness of pentavalent antimony, which is the traditional first-line treatment. Although monotherapy with other agents is available, the use of 2 drugs with different modes of action might increase efficacy, shorten treatment duration, enhance compliance, and/or reduce the risk of parasite resistance. To test the feasibility of a new approach to combination therapy in visceral leishmaniasis (also known a kala-azar), we treated Indian patients with a single infusion of liposomal amphotericin B (L-AmB), followed 1 day later by short-course oral miltefosine. We used a randomized, noncomparative, group-sequential, triangular design and assigned 181 subjects to treatment with 5 mg/kg of L-AmB alone (group A; 45 subjects), 5 mg/kg of L-AmB followed by miltefosine for 10 days (group B; 46 subjects) or 14 days (group C; 45 subjects), or 3.75 mg/kg of L-AmB followed by miltefosine for 14 days (group D; 45 subjects). When it became apparent that all regimens were effective, 45 additional, nonrandomized patients were assigned to receive 5 mg/kg of L-AmB followed by miltefosine for 7 days (group E). Each regimen was satisfactorily tolerated, and all 226 subjects showed initial apparent cure responses. Nine months after treatment, final cure rates were similar: group A, 91% (95% confidence interval [CI], 78%-97%]; group B, 98% (95% CI, 87%-100%); group C, 96% (95% CI, 84%-99%]; group D, 96% (95% CI, 84%-99%); and group E, 98% (95% CI, 87%-100%). These results suggest that treatment with single-dose L-AmB followed by 7-14 days of miltefosine is active against Indian kala-azar. This short-course, sequential regimen warrants additional testing in India and in those regions of endemicity where visceral leishmaniasis may be more difficult to treat. ClinicalTrials.gov identifier: NCT00370825 . |
| Author | Murray, Henry W. Vaillant, Michel Sundar, Shyam Agarwal, D. Agrawal, N. Chakravarty, J. Olliaro, Piero Rai, M. |
| Author_xml | – sequence: 1 givenname: Shyam surname: Sundar fullname: Sundar, Shyam email: drshyamsundar@hotmail.com organization: Kala-Azar Medical Research Center, Department of Medicine, Banaras Hindu University, Institute of Medical Sciences, Varanasi – sequence: 2 givenname: M. surname: Rai fullname: Rai, M. organization: Kala-Azar Medical Research Center, Department of Medicine, Banaras Hindu University, Institute of Medical Sciences, Varanasi – sequence: 3 givenname: J. surname: Chakravarty fullname: Chakravarty, J. organization: Kala-Azar Medical Research Center, Department of Medicine, Banaras Hindu University, Institute of Medical Sciences, Varanasi – sequence: 4 givenname: D. surname: Agarwal fullname: Agarwal, D. organization: Kala-Azar Medical Research Center, Department of Medicine, Banaras Hindu University, Institute of Medical Sciences, Varanasi – sequence: 5 givenname: N. surname: Agrawal fullname: Agrawal, N. organization: MLN Medical College, Allahabad, India – sequence: 6 givenname: Michel surname: Vaillant fullname: Vaillant, Michel organization: Clinical Epidemiology and Public Health Unit, Center for Health Studies, CRP-Santé, Luxembourg – sequence: 7 givenname: Piero surname: Olliaro fullname: Olliaro, Piero organization: UNICEF/UNDP/WB/WHO Special Programme for Research and Training in Tropical Diseases, Geneva, Switzerland – sequence: 8 givenname: Henry W. surname: Murray fullname: Murray, Henry W. organization: Department of Medicine, Weill Cornell Medical College, New York, New York |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20742767$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/18781879$$D View this record in MEDLINE/PubMed |
| BookMark | eNqF0dtu0zAcBvAIDbED8AaggDS4IWAnduxw13XsAIVdbCC0G8txnNXFsTPbUekT8Nq4pCoSUsVFlIN__uT_l8Nkz1gjk-QpBG8hoOU7XMGK5A-SA4gLkpXxdS8-A0wzRAu6nxx6vwAAQgrwo2QfUkLjVR0kv77IZXrjJA-dNCGd9L2zXMxTZdJL0yhu0m_KC-m4TmdS-XnHjeJe-ffptTJ3Wman1st0pnrrbRfRpOvnNkinREw4Sc-s1nYpm7Repddz60I2tYOLO67WiZ-VDrK1Xhn5OHnYcu3lk839KPl69uFmepHNrs4vp5NZJuIcIWtEQ2ve1IBgjjgtapA3AkFaYooBEaLBRVUigVpMm6pGjcCElpy2HAMQv1bFUfJ6zB1Mz1dLrjXrneq4WzEI2LpKNlYZ5atRxkbuB-kD69ZNaM2NtINnZYVJnufwvzCHCOASrxNf_gMXsQwTx42mqghEcJ32fIOGupPN39NtflkExxvAveC6ddwI5bcuBwTlpCTRvRmdcNZ7J1smVOBBWRMcV3rnuFu-s5cXI7RDv9s8G83CB-u2CoEC0PzPkNm4rnyQP7fr3P1g8eQEs4vvt-wUgY_n-PaEfSp-A4dd4ms |
| CODEN | CIDIEL |
| CitedBy_id | crossref_primary_10_1016_j_idc_2010_01_009 crossref_primary_10_3390_molecules21081045 crossref_primary_10_1016_j_exppara_2019_107728 crossref_primary_10_1080_13543784_2024_2400139 crossref_primary_10_1016_j_trstmh_2010_10_008 crossref_primary_10_1155_2010_617521 crossref_primary_10_1016_j_lfs_2022_121314 crossref_primary_10_2217_imt_09_40 crossref_primary_10_1371_journal_pntd_0000818 crossref_primary_10_3390_microorganisms8081117 crossref_primary_10_1016_j_bioorg_2020_104056 crossref_primary_10_1155_2014_646932 crossref_primary_10_1016_j_lpm_2010_09_023 crossref_primary_10_1016_j_ejmech_2013_02_038 crossref_primary_10_1371_journal_pntd_0000384 crossref_primary_10_1016_j_drudis_2017_06_004 crossref_primary_10_1016_j_actatropica_2018_03_016 crossref_primary_10_1007_s12551_013_0134_y crossref_primary_10_1371_journal_pntd_0004297 crossref_primary_10_1016_j_riam_2021_04_002 crossref_primary_10_1128_AAC_01150_15 crossref_primary_10_1007_s40261_012_0023_3 crossref_primary_10_1136_bmjgh_2018_000709 crossref_primary_10_1586_eri_12_170 crossref_primary_10_4103_1995_7645_345944 crossref_primary_10_1080_21678707_2019_1552853 crossref_primary_10_1016_j_exppara_2016_04_008 crossref_primary_10_1093_cid_civ004 crossref_primary_10_3389_fcimb_2023_1261074 crossref_primary_10_1016_j_ijid_2022_06_025 crossref_primary_10_1080_14787210_2024_2438627 crossref_primary_10_1021_acs_molpharmaceut_4c01133 crossref_primary_10_1371_journal_pntd_0002832 crossref_primary_10_1017_S0031182016002523 crossref_primary_10_1371_journal_pntd_0005706 crossref_primary_10_1517_17425240902802861 crossref_primary_10_1186_s13071_018_2937_y crossref_primary_10_12688_f1000research_15955_1 crossref_primary_10_36106_ijsr_7101101 crossref_primary_10_1016_j_cmi_2017_11_008 crossref_primary_10_1371_journal_pntd_0007843 crossref_primary_10_1080_14656566_2019_1609940 crossref_primary_10_1056_NEJMoa0903627 crossref_primary_10_1186_1745_6215_12_66 crossref_primary_10_1039_b922074g crossref_primary_10_2217_fmb_12_85 crossref_primary_10_1016_j_bmcl_2015_10_062 crossref_primary_10_1186_s12874_024_02256_9 crossref_primary_10_4103_1995_7645_354419 crossref_primary_10_1016_j_ejmech_2013_06_033 crossref_primary_10_1371_journal_pntd_0001974 crossref_primary_10_1517_14656560903555219 crossref_primary_10_1517_14656566_2013_755515 crossref_primary_10_1097_INF_0000000000001602 crossref_primary_10_1007_s42485_020_00035_w crossref_primary_10_1016_S0140_6736_10_62050_8 crossref_primary_10_1186_1756_3305_6_244 crossref_primary_10_1080_17460441_2020_1743674 crossref_primary_10_1128_AAC_05412_11 crossref_primary_10_1016_j_idc_2018_10_005 crossref_primary_10_1007_s12026_014_8535_y crossref_primary_10_1093_jac_dkx407 crossref_primary_10_1007_s10096_013_1999_1 crossref_primary_10_1111_j_1365_3156_2009_02306_x crossref_primary_10_1371_journal_pntd_0002130 crossref_primary_10_1517_14656566_2015_973850 crossref_primary_10_1517_17425240903548232 crossref_primary_10_1016_j_trstmh_2009_08_002 crossref_primary_10_1371_journal_pntd_0000599 crossref_primary_10_37349_eds_2024_00059 crossref_primary_10_1016_j_ijpddr_2019_08_004 crossref_primary_10_1039_C5RA02627J crossref_primary_10_1016_j_bioorg_2022_105872 crossref_primary_10_1080_00365540903104127 crossref_primary_10_1371_journal_pone_0094596 crossref_primary_10_1016_j_parint_2019_101934 crossref_primary_10_1371_journal_pntd_0005889 crossref_primary_10_1007_s00253_020_10856_w crossref_primary_10_1016_j_bmc_2010_02_043 crossref_primary_10_1517_14728214_2012_748036 crossref_primary_10_1111_j_1469_0691_2011_03630_x crossref_primary_10_1186_1745_6215_12_166 crossref_primary_10_3390_pathogens9100855 crossref_primary_10_1093_jac_dkt318 crossref_primary_10_1172_JCI41281 crossref_primary_10_2174_1871520618666181012093056 crossref_primary_10_1586_eri_11_32 crossref_primary_10_1177_2049936116646063 crossref_primary_10_1371_journal_pone_0017376 crossref_primary_10_1097_MOT_0b013e32834cdbb0 crossref_primary_10_3390_microorganisms9061228 crossref_primary_10_1371_journal_pntd_0001545 crossref_primary_10_1017_S0031182017002116 crossref_primary_10_2174_1568026620666200128160454 crossref_primary_10_3390_toxins11100563 crossref_primary_10_1186_s40249_016_0112_2 crossref_primary_10_7759_cureus_70104 crossref_primary_10_1016_j_ijpddr_2020_04_004 crossref_primary_10_3390_pathogens12050706 crossref_primary_10_1586_eri_10_78 crossref_primary_10_1016_S1473_3099_10_70011_6 crossref_primary_10_1111_cbdd_12566 crossref_primary_10_1021_jm9004835 crossref_primary_10_1097_QCO_0b013e32833fca9d crossref_primary_10_1093_jac_dkq542 crossref_primary_10_1097_QCO_0b013e32835c2198 crossref_primary_10_1371_journal_pntd_0002864 crossref_primary_10_1038_s41598_020_69276_5 crossref_primary_10_1111_j_1600_6143_2009_02915_x crossref_primary_10_1007_s40265_013_0133_0 crossref_primary_10_1093_jac_dks275 crossref_primary_10_1128_AAC_01129_17 crossref_primary_10_1093_cid_cis474 crossref_primary_10_1371_journal_pntd_0006094 crossref_primary_10_1021_acsinfecdis_9b00505 crossref_primary_10_1155_2011_645203 crossref_primary_10_1186_s13036_021_00267_4 crossref_primary_10_1007_s00044_019_02432_3 crossref_primary_10_1016_j_imu_2022_100954 crossref_primary_10_1111_ced_14919 crossref_primary_10_2217_fmb_10_92 crossref_primary_10_1517_14728210903153862 crossref_primary_10_4061_2011_571242 crossref_primary_10_1002_ddr_20452 crossref_primary_10_1093_cid_ciw670 crossref_primary_10_1007_s00430_015_0422_1 crossref_primary_10_1016_S1473_3099_15_00528_9 crossref_primary_10_1186_s13063_015_1018_1 |
| Cites_doi | 10.1086/377542 10.1016/S0140-6736(05)67629-5 10.1586/14787210.2.2.279 10.1056/NEJMoa066536 10.1016/S1473-3099(02)00347-X 10.1086/318122 10.1136/bmj.323.7310.419 10.1086/318121 10.1056/NEJMoa021556 10.1086/519690 10.4269/ajtmh.2002.66.143 10.1093/infdis/168.3.715 10.4269/ajtmh.2007.77.89 10.1086/380971 10.1086/520665 10.1016/0035-9203(92)90150-B 10.1016/S1473-3099(05)70296-6 10.1016/0035-9203(90)90263-E |
| ContentType | Journal Article |
| Copyright | Copyright 2008 Infectious Diseases Society of America 2008 by the Infectious Diseases Society of America 2008 2008 INIST-CNRS Copyright University of Chicago, acting through its Press Oct 15, 2008 |
| Copyright_xml | – notice: Copyright 2008 Infectious Diseases Society of America – notice: 2008 by the Infectious Diseases Society of America 2008 – notice: 2008 INIST-CNRS – notice: Copyright University of Chicago, acting through its Press Oct 15, 2008 |
| DBID | BSCLL AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7QL 7T2 7T7 7U7 7U9 8FD C1K FR3 H94 K9. M7N P64 7X8 ADTOC UNPAY |
| DOI | 10.1086/591972 |
| DatabaseName | Istex CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Bacteriology Abstracts (Microbiology B) Health and Safety Science Abstracts (Full archive) Industrial and Applied Microbiology Abstracts (Microbiology A) Toxicology Abstracts Virology and AIDS Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Algology Mycology and Protozoology Abstracts (Microbiology C) Biotechnology and BioEngineering Abstracts MEDLINE - Academic Unpaywall for CDI: Periodical Content Unpaywall |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Virology and AIDS Abstracts Technology Research Database Toxicology Abstracts Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Safety Science Abstracts Engineering Research Database Industrial and Applied Microbiology Abstracts (Microbiology A) Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | Virology and AIDS Abstracts Algology Mycology and Protozoology Abstracts (Microbiology C) MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1537-6591 |
| EndPage | 1006 |
| ExternalDocumentID | 10.1086/591972 1572478101 18781879 20742767 10_1086_591972 40308211 ark_67375_HXZ_D40JG5ZB_K |
| Genre | Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article Feature |
| GeographicLocations | Asia India Bihar India |
| GeographicLocations_xml | – name: India – name: Bihar India |
| GroupedDBID | --- ..I .2P .I3 .ZR 08P 0R~ 1TH 29B 2AX 2WC 36B 4.4 48X 53G 5GY 5RE 5VS 5WD 6J9 AABZA AACGO AACZT AAJKP AAJQQ AAMVS AANCE AAOGV AAPQZ AAPXW AAQQT AARHZ AAUAY AAUQX AAVAP ABBHK ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABLJU ABNGD ABNHQ ABOCM ABPLY ABPQP ABPTD ABQLI ABQNK ABTLG ABVGC ABWST ABXSQ ABXVV ACGFO ACGFS ACHIC ACPRK ACUFI ACUKT ACUTJ ACUTO ACYHN ADBBV ADGZP ADHKW ADHZD ADIPN ADNBA ADQBN ADQXQ ADRTK ADULT ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEUPB AEWNT AEXZC AFFNX AFFZL AFIYH AFOFC AFRAH AFXAL AGINJ AGORE AGQPQ AGQXC AGSYK AGUTN AHMBA AHMMS AHXPO AIAGR AJBYB AJEEA AJNCP ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APWMN AQKUS AQVQM ASPBG ATGXG AVWKF AXUDD AZFZN BAWUL BAYMD BCRHZ BEYMZ BHONS BSCLL BTRTY BVRKM C1A C45 CDBKE CS3 CZ4 DAKXR DCCCD DIK DILTD DU5 D~K E3Z EBS EE~ EJD EMOBN ENERS F5P F9B FECEO FEDTE FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC H13 H5~ HAR HQ3 HTVGU HVGLF HW0 HZ~ IOX IPSME J21 JAAYA JBMMH JENOY JHFFW JKQEH JLS JLXEF JPM JSG JST JXSIZ KAQDR KBUDW KOP KSI KSN L7B MHKGH MJL ML0 N4W N9A NGC NOMLY NOYVH NU- NVLIB O0~ O9- OAUYM OAWHX OCZFY ODMLO ODZKP OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P P6G PAFKI PB- PEELM PQQKQ Q1. Q5Y QBD RD5 ROX ROZ RUSNO RW1 RXO SA0 SJN TCURE TEORI TJX TMA TR2 W8F X7H YAYTL YKOAZ YXANX ~91 ~S- AAYOK AASNB ADACV ADJQC ADRIX AFXEN DOOOF ESX JSODD M49 AAYXX CITATION .GJ 1KJ 3O- 70D AAPGJ AAPNW AAWDT ABKDP ABNKS ABSMQ ABZBJ ACFRR ACPQN ACVCV ACZBC ADEYI ADMTO ADOCK AEKPW AFFQV AFSHK AFYAG AGKEF AGKRT AGMDO AHGBF AI. AIJHB AJDVS APJGH AQDSO AVNTJ BZKNY EIHJH IQODW J5H MBLQV OBFPC O~Y VH1 Y6R ZGI CGR CUY CVF ECM EIF NPM 7QL 7T2 7T7 7U7 7U9 8FD C1K FR3 H94 K9. M7N P64 7X8 ADTOC UNPAY |
| ID | FETCH-LOGICAL-c483t-dcd8badb075a4a83b02dc418658507ccd53964c4f58d9b4dc5786a8fa500c4f93 |
| IEDL.DBID | UNPAY |
| ISSN | 1058-4838 1537-6591 |
| IngestDate | Wed Oct 01 16:04:43 EDT 2025 Wed Oct 01 16:57:42 EDT 2025 Thu Oct 02 07:53:41 EDT 2025 Tue Oct 07 05:46:44 EDT 2025 Thu Apr 03 06:56:37 EDT 2025 Mon Jul 21 09:10:59 EDT 2025 Wed Oct 01 02:09:02 EDT 2025 Thu Apr 24 23:12:51 EDT 2025 Wed Sep 11 04:50:48 EDT 2024 Thu Jun 19 15:26:45 EDT 2025 Sat Sep 20 11:01:49 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Keywords | Antineoplastic agent Protozoal disease Single dose Oral administration Phospholipid Kala azar Leishmaniasis Parasitosis Infection Antiprotozoal agent Miltefosine Antibiotic Antifungal agent Treatment Amphotericin B Polyenic compound Lysophospholipid Parasiticide Indian |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c483t-dcd8badb075a4a83b02dc418658507ccd53964c4f58d9b4dc5786a8fa500c4f93 |
| Notes | ark:/67375/HXZ-D40JG5ZB-K istex:1A8A636C1426548469C4FC297DC0181D59CE3891 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://academic.oup.com/cid/article-pdf/47/8/1000/984954/47-8-1000.pdf |
| PMID | 18781879 |
| PQID | 219971411 |
| PQPubID | 48300 |
| PageCount | 7 |
| ParticipantIDs | unpaywall_primary_10_1086_591972 proquest_miscellaneous_69572221 proquest_miscellaneous_21405652 proquest_journals_219971411 pubmed_primary_18781879 pascalfrancis_primary_20742767 crossref_citationtrail_10_1086_591972 crossref_primary_10_1086_591972 oup_primary_10_1086_591972 jstor_primary_40308211 istex_primary_ark_67375_HXZ_D40JG5ZB_K |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2008-10-15 |
| PublicationDateYYYYMMDD | 2008-10-15 |
| PublicationDate_xml | – month: 10 year: 2008 text: 2008-10-15 day: 15 |
| PublicationDecade | 2000 |
| PublicationPlace | Chicago, IL |
| PublicationPlace_xml | – name: Chicago, IL – name: United States – name: Oxford |
| PublicationTitle | Clinical infectious diseases |
| PublicationTitleAbbrev | Clinical Infectious Diseases |
| PublicationTitleAlternate | Clinical Infectious Diseases |
| PublicationYear | 2008 |
| Publisher | The University of Chicago Press University of Chicago Press Oxford University Press |
| Publisher_xml | – name: The University of Chicago Press – name: University of Chicago Press – name: Oxford University Press |
| References | Sundar S (rf15_460) 2002; 66 rf19_464 rf1_446 rf4_449 rf10_455 rf12_457 rf6_451 rf16_461 rf7_452 Seaman J (rf8_453) 1993; 168 Melaku Y (rf9_454) 2007; 77 rf2_447 rf3_448 rf11_456 rf13_458 rf14_459 rf17_462 rf5_450 Sundar S (rf18_463) 2005; 83 |
| References_xml | – ident: rf12_457 doi: 10.1086/377542 – ident: rf2_447 doi: 10.1016/S0140-6736(05)67629-5 – ident: rf16_461 doi: 10.1586/14787210.2.2.279 – ident: rf5_450 doi: 10.1056/NEJMoa066536 – ident: rf10_455 doi: 10.1016/S1473-3099(02)00347-X – ident: rf13_458 doi: 10.1086/318122 – ident: rf11_456 doi: 10.1136/bmj.323.7310.419 – ident: rf1_446 doi: 10.1086/318121 – ident: rf4_449 doi: 10.1056/NEJMoa021556 – ident: rf17_462 doi: 10.1086/519690 – volume: 66 start-page: 143 year: 2002 ident: rf15_460 publication-title: Am J Trop Med Hyg doi: 10.4269/ajtmh.2002.66.143 – volume: 168 start-page: 715 year: 1993 ident: rf8_453 publication-title: J Infect Dis doi: 10.1093/infdis/168.3.715 – volume: 77 start-page: 89 year: 2007 ident: rf9_454 publication-title: Am J Trop Med Hyg doi: 10.4269/ajtmh.2007.77.89 – volume: 83 start-page: 394 year: 2005 ident: rf18_463 publication-title: Bull World Health Organ – ident: rf19_464 doi: 10.1086/380971 – ident: rf14_459 doi: 10.1086/520665 – ident: rf7_452 doi: 10.1016/0035-9203(92)90150-B – ident: rf3_448 doi: 10.1016/S1473-3099(05)70296-6 – ident: rf6_451 doi: 10.1016/0035-9203(90)90263-E |
| SSID | ssj0011805 |
| Score | 2.3542511 |
| Snippet | Background. In Bihar, India, home to nearly one-half of the world's burden of visceral leishmaniasis, drug resistance has ended the usefulness of pentavalent... Background, In Bihar, India, home to nearly one-half of the world's burden of visceral leishmaniasis, drug resistance has ended the usefulness of pentavalent... Background . In Bihar, India, home to nearly one-half of the world's burden of visceral leishmaniasis, drug resistance has ended the usefulness of pentavalent... In Bihar, India, home to nearly one-half of the world's burden of visceral leishmaniasis, drug resistance has ended the usefulness of pentavalent antimony,... |
| SourceID | unpaywall proquest pubmed pascalfrancis crossref oup jstor istex |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1000 |
| SubjectTerms | Adult Amphotericin B - administration & dosage Amphotericin B - adverse effects Amphotericin B - therapeutic use Antibiotics. Antiinfectious agents. Antiparasitic agents Antifungal agents Antimony Antiparasitic agents Articles and Commentaries Biological and medical sciences Dosage Drug resistance Drug therapy Drug Therapy, Combination Experimentation Female Human protozoal diseases Humans India Infectious diseases Intravenous injections Leishmaniasis, Visceral - drug therapy Leshmaniasis Male Medical cures Medical research Medical sciences Parasite resistance Parasites Parasitic diseases Pharmacology. Drug treatments Phosphorylcholine - administration & dosage Phosphorylcholine - adverse effects Phosphorylcholine - analogs & derivatives Phosphorylcholine - therapeutic use Protozoal diseases Risk reduction Skin diseases Sodium Treatment Outcome Tropical medicine Vector-borne diseases Visceral leishmaniasis |
| Title | New Treatment Approach in Indian Visceral Leishmaniasis: Single-Dose Liposomal Amphotericin B Followed by Short-Course Oral Miltefosine |
| URI | https://api.istex.fr/ark:/67375/HXZ-D40JG5ZB-K/fulltext.pdf https://www.jstor.org/stable/40308211 https://www.ncbi.nlm.nih.gov/pubmed/18781879 https://www.proquest.com/docview/219971411 https://www.proquest.com/docview/21405652 https://www.proquest.com/docview/69572221 https://academic.oup.com/cid/article-pdf/47/8/1000/984954/47-8-1000.pdf |
| UnpaywallVersion | publishedVersion |
| Volume | 47 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1537-6591 dateEnd: 20241102 omitProxy: true ssIdentifier: ssj0011805 issn: 1058-4838 databaseCode: DIK dateStart: 19960101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3LctMwFNWUZIbHMLwLbiHVAtg5sR1JltmllDR9pDDThgndeGRLnnjq2pk6mVJW7NnwjXwJV37RAh02LGNdybbuiXQsXZ2L0EsuAspcRUw3Yp5JQk5NmIQjM1KCUKkFSYrjY-MDNpqQ3SmdrqDt-iyMqKLCu82RBvBJ1YnmXEY94vZ4Ty9K9zwO5J7ABVMLlFpWF4pvoDajQMpbqD05-DD4VOx10mLJjJfKqa4JBvalLEPwy3OdK9NSW_fw5zpCsT76dncucui3qEx48TdGegfdWqZzcXEukuTSLDW8j2b1-5XBKSfd5SLohl9-k378Dx3wAN2rmCwelJUeohWVPkI3x9Ve_WP0DcZPfFTHseNBJV6O4xTvpBqV-GOch3pJDO-rOJ9pIQ6Rx_kbfAjTaaJ-fP2-leUK78fzLM9O9a0AeZnWloYb4E08BAhn50ri4AIfzuAzAmroFHxQ571udRwnCxVlOrD_CZoM3x29HZlV6gczBFctTBlKHggZAKERRPB-YDkyJDYHvgQENgwl7XuMhCSiXHoBkSEMPEzwSOd3gKtefxW10ixVzxCmXAUuExFxJCOKeZ6ylCVcJ5As4FT1DfSq9rwfVrroOj1H4hf785z5JUIMtNHYzUslkD8sXhfAaYrF2YmOm3OpP5oe-1vE2t2mx5v-noFWC2Q1hqRQDbJtA62B269tvnMFgY2Zo9c3XOYaaL2GpF-NRLnv6Egim-i2N5rSU-3fREdTZ0ttAqydUed6C-ZRF4gktPG0RPqvR-Qu1wnrDYQb6F_z_Gv_NllHt51Kb9imz1FrcbZUL4D0LYIOfO7s7HWqv_VPbANQ3w |
| linkProvider | Unpaywall |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3LctMwFNWUZIbHMLwLbqHVAtg5sR29zC6lpKU0hZk2TOjGI1vyxNPUztTJlLJiz4Zv5Eu48osWyLBhaetKdnSPpRPp6lyEngsZUsY1sXnMfJtEgtowCcd2rCWhygiSFMfHhgdsd0T2xnS8gnbqszCyigrvNEcawCdVJ9ozFXcJ74quWZTu-gLIPYEbthEodZwOFF9DbUaBlLdQe3Twof-p2OukxZKZKJVTuQ0G7qUsQ3Dlc-_KtNQ2Pfy5jlCsj77dnskc-i0uE178jZHeQjcW6UxenMvp9NIsNbiLJvXvK4NTTjqLediJvvwm_fgfOuAeulMxWdwvK91HKzp9gK4Pq736h-gbjJ_4qI5jx_1KvBwnKX6bGlTij0kemSUxvK-TfGKEOGSe5K_wIUynU_3j6_ftLNd4P5lleXZqHgXIy4y2NDwAb-EBQDg71wqHF_hwAn8joIZJwQd13ptWh8l0ruPMBPY_QqPBm6PXu3aV-sGOwFVzW0VKhFKFQGgkkaIXOp6KiCuALwGBjSJFez4jEYmpUH5IVAQDD5MiNvkd4K7fW0WtNEv1E4Sp0CFnMiaeYkQz39eOdiT3QsVCQXXPQi9qzwdRpYtu0nNMg2J_XrCgRIiFNhu7WakE8ofFywI4TbE8OzFxc5wGu-PjYJs4ezv0eCt4Z6HVAlmNISlUg1zXQmvg9qXNb1xBYGPmmfUNzriF1mtIBtVIlAeeiSRyiWl7syk9Nf6dmmjqbGFMgLUz6i23YD7lQCShjccl0n-9ouDCJKy3EG6gv-T91_5tso5uepXesEufotb8bKGfAembhxvVB_0TjHBP5g |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=New+Treatment+Approach+in+Indian+Visceral+Leishmaniasis+%3A+Single-Dose+Liposomal+Amphotericin+B+Followed+by+Short-Course+Oral+Miltefosine&rft.jtitle=Clinical+infectious+diseases&rft.au=SUNDAR%2C+Shyam&rft.au=RAI%2C+M&rft.au=CHAKRAVARTY%2C+J&rft.au=AGARWAL%2C+D&rft.date=2008-10-15&rft.pub=University+of+Chicago+Press&rft.issn=1058-4838&rft.volume=47&rft.issue=8&rft.spage=1000&rft.epage=1006&rft_id=info:doi/10.1086%2F591972&rft.externalDBID=n%2Fa&rft.externalDocID=20742767 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1058-4838&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1058-4838&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1058-4838&client=summon |